Evidence of a clinically significant drug‐drug interaction between cannabidiol and tacrolimus

Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment for refractory epilepsy (Epidiolex; GW Pharmaceuticals). CBD is metabolized by cytochrome P450 (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2019-10, Vol.19 (10), p.2944-2948
Hauptverfasser:	Leino, Abbie D., Emoto, Chie, Fukuda, Tsuyoshi, Privitera, Michael, Vinks, Alexander A., Alloway, Rita R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult alternative and complementary medicine Anticonvulsants Cannabidiol - metabolism Cannabidiol - therapeutic use Cannabinoids Cannabis Case reports clinical research/practice Clinical significance Cytochrome P450 Drug interaction Drug Interactions Epilepsy Epilepsy - complications Epilepsy - drug therapy Epilepsy - metabolism Epilepsy - pathology FDA approval Female Humans immunosuppressant ‐ calcineurin inhibitor: tacrolimus immunosuppression/immune modulation Immunosuppressive Agents - metabolism Immunosuppressive Agents - therapeutic use Nephritis, Interstitial - complications Nephritis, Interstitial - drug therapy Nephritis, Interstitial - metabolism Nephritis, Interstitial - pathology pharmacology Prognosis Tacrolimus Tacrolimus - metabolism Tacrolimus - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!